These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22103814)

  • 1. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C.
    Fontana RJ; Litman HJ; Dienstag JL; Bonkovsky HL; Su G; Sterling RK; Lok AS;
    Liver Int; 2012 Apr; 32(4):665-74. PubMed ID: 22103814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. YKL-40-gene polymorphism affects acute cellular rejection and fibrosis progression after transplantation for hepatitis C virus-induced liver disease.
    Eurich D; Neumann UP; Boas-Knoop S; Neuhaus R; Kiessling A; Yahyazadeh A; Trautwein C; Wasmuth H; Puhl G; Neuhaus P; Bahra M
    J Gastroenterol Hepatol; 2013 Jan; 28(1):153-60. PubMed ID: 22989351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
    Lok AS; Everhart JE; Chung RT; Kim HY; Everson GT; Hoefs JC; Greenson JK; Sterling RK; Lindsay KL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Ghany MG; Morishima C;
    Hepatology; 2009 Jun; 49(6):1828-37. PubMed ID: 19291787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
    Fontana RJ; Dienstag JL; Bonkovsky HL; Sterling RK; Naishadham D; Goodman ZD; Lok AS; Wright EC; Su GL;
    Gut; 2010 Oct; 59(10):1401-9. PubMed ID: 20675691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.
    Fontana RJ; Bonkovsky HL; Naishadham D; Dienstag JL; Sterling RK; Lok AS; Su GL;
    Clin Gastroenterol Hepatol; 2009 Feb; 7(2):219-26. PubMed ID: 19068241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.
    Cieśla A; Bociąga-Jasik M; Sobczyk-Krupiarz I; Głowacki MK; Owczarek D; Cibor D; Sanak M; Mach T
    World J Gastroenterol; 2012 Sep; 18(35):4892-7. PubMed ID: 23002361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promoter polymorphisms in the chitinase 3-like 1 gene influence the serum concentration of YKL-40 in Danish patients with rheumatoid arthritis and in healthy subjects.
    Nielsen KR; Steffensen R; Boegsted M; Baech J; Lundbye-Christensen S; Hetland ML; Krintel SB; Johnsen HE; Nyegaard M; Johansen JS
    Arthritis Res Ther; 2011 Jun; 13(3):R109. PubMed ID: 21714862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection.
    Berres ML; Papen S; Pauels K; Schmitz P; Zaldivar MM; Hellerbrand C; Mueller T; Berg T; Weiskirchen R; Trautwein C; Wasmuth HE
    J Hepatol; 2009 Feb; 50(2):370-6. PubMed ID: 19070929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.
    Valenti L; Aghemo A; Stättermayer AF; Maggioni P; De Nicola S; Motta BM; Rumi MG; Dongiovanni P; Ferenci P; Colombo M; Fargion S
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1434-42. PubMed ID: 22530607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
    Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
    AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic fibrosis in patients with chronic hepatitis C assessed by transient elastography: implications for determining the efficacy of antiviral therapy.
    Mendoza J; Trapero-Marugán M; González-Moreno L; Jones EA; Gómez-Domínguez E; Moreno-Otero R
    Rev Esp Enferm Dig; 2010 Jul; 102(7):426-34. PubMed ID: 20617863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
    Morishima C; Shiffman ML; Dienstag JL; Lindsay KL; Szabo G; Everson GT; Lok AS; Di Bisceglie AM; Ghany MG; Naishadham D; Morgan TR; Wright EC;
    Am J Gastroenterol; 2012 Sep; 107(9):1388-98. PubMed ID: 22688849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
    Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
    PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
    Shiffman ML; Morishima C; Dienstag JL; Lindsay KL; Hoefs JC; Lee WM; Wright EC; Naishadham D; Everson GT; Lok AS; Di Bisceglie AM; Bonkovsky HL; Ghany MG;
    Gastroenterology; 2009 Dec; 137(6):1986-94. PubMed ID: 19747918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PROGNOSTIC VALUE OF THE COMBINATION OF BLOOD GROUP SPECIFICITY AND INTERLEUKIN 28B GENE POLYMORPHISM FOR ESTIMATION OF EFFICIENCY OF THERAPY WITH THE USE OF PEGYLATED INTERFERON α-2 AND RIBAVARIN IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C].
    Ogurtsov PP; Kukhareva EI
    Klin Med (Mosk); 2016; 94(3):224-30. PubMed ID: 27522730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin.
    Pascu O; Voiculescu M; Gheorghe L; Micu L; Seicean A; Iliescu L; Mocan T; Ceauşu E; Mateescu B
    Rom J Intern Med; 2011; 49(2):105-12. PubMed ID: 22303601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
    Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
    Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis.
    Kim KH; Jang BK; Chung WJ; Hwang JS; Kweon YO; Tak WY; Lee HJ; Lee CH; Suh JI
    Korean J Hepatol; 2011 Sep; 17(3):220-5. PubMed ID: 22102389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lipid kinetics during dual antiviral therapy in patients with chronic hepatitis C].
    Jiménez Macías FM; Barrero Alor F; Casado Monge PG; Ramos Lora M; Pujol de la Llave E; Ruíz-Frutos C
    Med Clin (Barc); 2015 Jun; 144(12):536-43. PubMed ID: 24726260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variation in chitinase 3-like 1 (CHI3L1) contributes to asthma severity and airway expression of YKL-40.
    Gomez JL; Crisafi GM; Holm CT; Meyers DA; Hawkins GA; Bleecker ER; Jarjour N; ; Cohn L; Chupp GL
    J Allergy Clin Immunol; 2015 Jul; 136(1):51-58.e10. PubMed ID: 25592985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.